A Phase 4 interventional study of 1.5% levofloxacin ophthalmic solution and 0.5% moxifloxacin hydrochloride ophthalmic solution in Healthy, sponsored by Santen Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-06.
Sponsored by Santen Inc. · Phase 4, Interventional, and Basic science
The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
Santen Inc. is the lead sponsor of 31 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
described in intervention
Drug: 0.5% moxifloxacin hydrochloride ophthalmic solution
described in intervention
Drug: 0.3% gatifloxacin ophthalmic solution
described in intervention
Drug: 1.5% levofloxacin ophthalmic solution
1 drop instilled at each visit
1 drop instilled at each visit
1 drop instilled at each visit
Concentration of levofloxacin, moxifloxacin or gatifloxacin in tears
Time frame: 15 minutes, 2, 6, 12 and 24 hours
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Inc.